LATEST NEWS   BUDI MADANI: BUDI Agri-Commodity will continue in a targeted manner to help smallholders, entrepreneurs and vulnerable groups - PM Anwar | Plantation and Commodities Ministry will continue to study other medium and long-term mitigation steps such as enhancing price controls, anti-profiteering in agricultural inputs -- Akmal Nasrullah | Axiata's net profit rose to RM273.80 million in 1Q 2026 from RM159.84 million in 1Q 2025, driven by higher EBITDA, foreign exchange gains, and lower finance costs | Ministry of Plantation and Commodities should explore new markets for exports of palm oil products -- Akmal Nasrullah | MISC Bhd posted higher net profit of RM741.4 million in 1Q 2026, compared with RM705.7 million in 1Q 2025 | 

Spring Bio Solution Launches First Free Pharma Intelligence Platform

KUALA LUMPUR, June 12 (Bernama) -- Spring Bio Solution, a global leader in comparator sourcing and clinical trial supplies, has launched NCE Grid, touted as the world’s first free new chemical entity (NCE-1) intelligence platform — built to decode, centralise, and visualise Paragraph IV (Para IV) opportunities in real-time.

In a statement, the company said the platform addresses long-standing challenges in the pharmaceutical industry, where tracking NCE exclusivity expirations and Para IV filings has been a fragmented and manual process, often relying on spreadsheets and siloed databases.

Spring Bio Solution Founder and Chief Executive Officer, Salim Shaikh said: “We created NCE Grid because we saw too many companies struggle with fragmented insights and missed opportunities. 

“In a race where timing is everything, our platform brings clarity, speed, and a competitive edge to decision-makers. When you think Para IV, think NCE Grid — your trusted guide for strategic drug development.” 

NCE Grid consolidates key data points, including molecule, innovator name, NCE-1 date, revenue, therapeutic applications, sales forecasts, and percentage of compound annual growth rates (CAGR), into one intuitive platform.

The platform aims to support regulatory, strategy, and portfolio teams by offering real-time insights to identify and prioritise first-to-file opportunities, a crucial factor for generic pharmaceutical companies competing for market exclusivity.

-- BERNAMA